Optima Management of the Anticoagulated Patient with Life-Threatening Bleeding

Thursday, November 11, 2021, 12:00 AM - Friday, November 11, 2022, 11:00 PM, Online Course, Cincinnati, OH

AMA PRA Category 1 Credits™ (1.00 hours), AMA PRA Category 1 Credits™ Designated (1.00 hours)


The impact of the ever-changing COVID-19 pandemic is creating a rapidly evolving clinical environment for healthcare providers (HCPs). As a result, HCPs are challenged to keep up with the most current clinical information, while constantly evolving their approaches to the management of anticoagulated patients with severe bleeding. As a result, innovative approaches are required to educate these HCPs on how they can make a positive impact on patient care and improve clinical outcomes in the new COVID-19 world, especially as it relates to emergency medicine. 

Patients presenting to the hospital with severe bleeding and underlying treatment with factor Xa or factor IIa inhibitors represent an enormous challenge to emergency physicians, hospitalists, critical care physicians, cardiologists, trauma/general surgeons, hematologists, and pre-hospital care physicians. Intracranial bleeding, intra-abdominal or thoracic trauma, gastrointestinal bleeding, and bleeding from any non-compressible source represent true life-threatening emergencies. Treatment of severe bleeding in patients receiving Factor Xa inhibitors currently involves using non-specific therapy such as blood factor replacement (packed red blood cells (pRBCs), fresh frozen plasma, and platelets). 

With the development and approval of recent reversal agents, treatment of severe bleeding can now be specifically directed at the source of the coagulopathy combined with appropriate factor blood factor replacement. Over the last 18 months, nationally recognized guidelines have provided clear direction on how best to manage these types of major bleeding events. Our assessment of learners within the EMCREG-International/TotalCME network suggests that knowledge and implementation gaps remain. As data emerge regarding new approaches to therapy, clinicians need to be aware of these new and effective approaches and to assess the benefits and risks associated with each of these approaches.

This program, recorded live as a symposium presented during the 2021 EUSEM Congress in Lisbon, discusses therapeutic approaches and reversal strategies of patients on anticoagulation with life-threatening bleeds and how to develop a hospital critical pathway for severe bleeding in the anticoagulated patient.

To view this enduring material, please go to: www.MedEdOTG.com

There is no registration fee for this activity.  

Release Date: 11/11/2021
Expiration Date: 11/11/2022
Estimated time to complete activity: 1 hour 

 

1. Describe the indications for anticoagulation and agents including coumadin, factor IIa, and factor Xa inhibitors
2. Compare and contrast the treatment of intracranial, intraspinal, and gastrointestinal bleeding in the anticoagulated patient
3. Differentiate and improve care for traumatized anticoagulated patients presenting to the ED requiring surgical treatment and care in the surgical ICU

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati Office of Continuing Medical Education, EMCREG-International and TotalCME, Inc.

The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this online activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Continuing Nurse Education
Approved contact hours: 1.0 total continuing education contact hour for nurses are approved by the Ohio Board of Nursing through the OBN Approver Unit at the University of Cincinnati College of Nursing, Continuing Education Program (OBN-011-93). Contact hours are valid in most states. Program: 211027-1

Continuing Pharmacy Education
The University of Cincinnati James L. Winkle College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0050-9999-21-077-H01-P. This activity is worth a total of 1.0 CEUs (1.0 contact hour). 



The opinions expressed during the live activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development. 

Mitigation of Relevant Financial Relationships

The University of Cincinnati adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests) over the last 24-months. All relevant relationships have been mitigated prior to the commencement of the activity.

Information regarding the new updated ACCME Standards for Integrity and Independence in Accredited Continuing Education can be found on the ACCME website.

No faculty are available for this activity at this time.

Supported by an educational grant from Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease